Detalhe da pesquisa
1.
Histone demethylase LSD1 is required for germinal center formation and BCL6-driven lymphomagenesis.
Nat Immunol
; 20(1): 86-96, 2019 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30538335
2.
LSD1 inhibition exerts its antileukemic effect by recommissioning PU.1- and C/EBPα-dependent enhancers in AML.
Blood
; 131(15): 1730-1742, 2018 04 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-29453291
3.
Lysine specific demethylase 1 inactivation enhances differentiation and promotes cytotoxic response when combined with all-trans retinoic acid in acute myeloid leukemia across subtypes.
Haematologica
; 104(6): 1156-1167, 2019 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-30514804
4.
A stem cell-like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable silencing.
Nat Genet
; 39(2): 237-42, 2007 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-17211412
5.
DNMT1 modulates gene expression without its catalytic activity partially through its interactions with histone-modifying enzymes.
Nucleic Acids Res
; 40(10): 4334-46, 2012 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-22278882
6.
Inhibiting Type I Arginine Methyltransferase Activity Promotes T Cell-Mediated Antitumor Immune Responses.
Cancer Immunol Res
; 10(4): 420-436, 2022 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35181787
7.
Double strand breaks can initiate gene silencing and SIRT1-dependent onset of DNA methylation in an exogenous promoter CpG island.
PLoS Genet
; 4(8): e1000155, 2008 Aug 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-18704159
8.
Discovery of a first-in-class reversible DNMT1-selective inhibitor with improved tolerability and efficacy in acute myeloid leukemia.
Nat Cancer
; 2(10): 1002-1017, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34790902
9.
Lysine-Specific Demethylase 1 Mediates AKT Activity and Promotes Epithelial-to-Mesenchymal Transition in PIK3CA-Mutant Colorectal Cancer.
Mol Cancer Res
; 18(2): 264-277, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31704733
10.
Identification of hnRNP-A1 as a pharmacodynamic biomarker of type I PRMT inhibition in blood and tumor tissues.
Sci Rep
; 10(1): 22155, 2020 12 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-33335114
11.
Targeting epigenetic modifications in cancer therapy: erasing the roadmap to cancer.
Nat Med
; 25(3): 403-418, 2019 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-30842676
12.
Phase I, Open-Label, Dose-Escalation Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of GSK2879552 in Relapsed/Refractory SCLC.
J Thorac Oncol
; 14(10): 1828-1838, 2019 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31260835
13.
Lsd1 as a therapeutic target in Gfi1-activated medulloblastoma.
Nat Commun
; 10(1): 332, 2019 01 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-30659187
14.
Rational Targeting of Cooperating Layers of the Epigenome Yields Enhanced Therapeutic Efficacy against AML.
Cancer Discov
; 9(7): 872-889, 2019 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-31076479
15.
Anti-tumor Activity of the Type I PRMT Inhibitor, GSK3368715, Synergizes with PRMT5 Inhibition through MTAP Loss.
Cancer Cell
; 36(1): 100-114.e25, 2019 07 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-31257072
16.
Targeting enhancer switching overcomes non-genetic drug resistance in acute myeloid leukaemia.
Nat Commun
; 10(1): 2723, 2019 06 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-31222014
17.
Targeting Histone Methylation in Cancer.
Cancer J
; 23(5): 292-301, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-28926430
18.
Phase I trials of the lysine-specific demethylase 1 inhibitor, GSK2879552, as mono- and combination-therapy in relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes.
Leuk Lymphoma
; 63(2): 463-467, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34927529
19.
Antitumor activity of LSD1 inhibitors in lung cancer.
Mol Cell Oncol
; 3(2): e1117700, 2016 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-27308632
20.
Structure-Based Design of a Novel SMYD3 Inhibitor that Bridges the SAM-and MEKK2-Binding Pockets.
Structure
; 24(5): 774-781, 2016 05 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-27066749